Update on the use of immunoglobulin in human disease: A review of evidence

• Published in: Journal of allergy and clinical immunology Vol. 139; no. 3; pp. S1 - S46
• Main Authors: Perez, Elena E., Orange, Jordan S., Bonilla, Francisco, Chinen, Javier, Chinn, Ivan K., Dorsey, Morna, El-Gamal, Yehia, Harville, Terry O., Hossny, Elham, Mazer, Bruce, Nelson, Robert, Secord, Elizabeth, Jordan, Stanley C., Stiehm, E. Richard, Vo, Ashley A., Ballow, Mark
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2017
• Subjects: adverse events; Allergy and Immunology; Animals; autoimmunity; Evidence-Based Medicine; Humans; IGIV; Immune globulin; immune modulating; Immunity, Humoral; immunoglobulin; Immunoglobulins - therapeutic use; Immunoglobulins, Intravenous - therapeutic use; Immunologic Deficiency Syndromes - immunology; Immunologic Deficiency Syndromes - therapy; Immunomodulation; Injections, Subcutaneous; IVIG; Practice Guidelines as Topic; primary immunodeficiency; SCIG; transfusion; immunomodulation; CLL; FDA; RCT; APS; ITP; SCIG; WAS; transfusion; GVHD; XLA; SCID; SC; immune modulating; CVID; DSA; THI; Immune globulin; primary immunodeficiency; GBS; KD; MG; BMI; MM; SCORAD; AD; JIA; immunoglobulin; MS; IVIG; IGIV; ISR; VOD; adverse events; CIDP; IV; MMN; RA; AT; autoimmunity; RSV; PE; PI; LEMS; PAN; HAART; Transient hypogammaglobulinemia; Multiple sclerosis; Common variable immunodeficiency; Donor-specific HLA antigen; Juvenile idiopathic arthritis; Veno-occlusive disease; Body mass index; Multifocal motor neuropathy; Atopic dermatitis; US Food and Drug Administration; Wiskott-Aldrich syndrome; Subcutaneous; Severity scoring of Alzheimer disease; Randomized controlled trial; Guillain-Barré syndrome; Lambert-Eaton myasthenic syndrome; Rheumatoid arthritis; Ataxia telangiectasia; Highly active antiretroviral treatment; Anti–phospholipid antibody syndrome; Subcutaneous immunoglobulin; Severe combined immunodeficiency; Polyarteritis nodosa; Multiple myeloma; X-linked agammaglobulinemia; Plasma exchange; Kawasaki disease; Myasthenia gravis; Infusion site reaction; Graft-versus-host disease; Intravenous; Intravenous immunoglobulin; Chronic lymphocytic leukemia; Respiratory syncytial virus; Immune thrombocytopenic purpura; Chronic inflammatory demyelinating polyneuropathy
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2016.09.023

Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.